{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:35:43Z","timestamp":1782282943412,"version":"3.54.5"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014620","name":"Micropalaeontological Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.esmoop.2025.105921","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T13:33:02Z","timestamp":1765027982000},"page":"105921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Montelukast as a novel therapeutic approach in metastatic uveal melanoma harboring a CYSLTR2 mutation: a translational case report"],"prefix":"10.1016","volume":"11","author":[{"given":"D.","family":"Smarsly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Kreuzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Langhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9031-1368","authenticated-orcid":false,"given":"M.","family":"Scheffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Siebolts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lennartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Koll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-C.","family":"Glaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9142-5423","authenticated-orcid":false,"given":"C.","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.esmoop.2025.105921_bib1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3390\/cells13121023","article-title":"Recent advances in molecular and genetic research on uveal melanoma","volume":"13","author":"Fuentes-Rodriguez","year":"2024","journal-title":"Cells"},{"issue":"13","key":"10.1016\/j.esmoop.2025.105921_bib2","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105921_bib3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","article-title":"Advances in the clinical management of uveal melanoma","volume":"20","author":"Carvajal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105921_bib4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.hpb.2019.11.002","article-title":"Systematic review of liver directed therapy for uveal melanoma hepatic metastases","volume":"22","author":"Rowcroft","year":"2020","journal-title":"HPB (Oxford)"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105921_bib5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/ijms23010120","article-title":"Cysteinyl leukotriene pathway and cancer","volume":"23","author":"Tsai","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105921_bib6","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.3390\/cancers12102950","article-title":"High cysteinyl leukotriene receptor 1 expression correlates with poor survival of uveal melanoma patients and cognate antagonist drugs modulate the growth, cancer secretome, and metabolism of uveal melanoma cells","volume":"12","author":"Slater","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105921_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12885-021-07865-x","article-title":"Involvement of mutant and wild-type CYSLTR2 in the development and progression of uveal nevi and melanoma","volume":"21","author":"Nell","year":"2021","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105921_bib8","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/ng.3549","article-title":"Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma","volume":"48","author":"Moore","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.esmoop.2025.105921_bib9","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.015352","article-title":"Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling","volume":"296","author":"Ceraudo","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.esmoop.2025.105921_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.plefa.2018.12.002","article-title":"Characterization of cysteinyl leukotriene-related receptors and their interactions in a mouse model of asthma","volume":"141","author":"Trinh","year":"2019","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105921_bib11","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study","volume":"39","author":"Pelster","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105921_bib12","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab plus ipilimumab for treatment-na\u00efve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105921_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000331","article-title":"Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study","volume":"8","author":"Najjar","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105921_bib14","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/annonc\/mdl309","article-title":"A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma","volume":"17","author":"Schmittel","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105921_bib15","doi-asserted-by":"crossref","first-page":"9031","DOI":"10.1200\/jco.2013.31.15_suppl.9031","article-title":"Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma","volume":"31","author":"Sacco","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105921_bib16","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3389\/fphar.2020.01289","article-title":"Leukotrienes in tumor-associated inflammation","volume":"11","author":"Tian","year":"2020","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105921_bib17","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4049\/jimmunol.1700603","article-title":"Type 2 cysteinyl leukotriene receptors drive IL-33-dependent type 2 immunopathology and aspirin sensitivity","volume":"200","author":"Liu","year":"2018","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105921_bib18","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.4049\/jimmunol.1201865","article-title":"Cysteinyl leukotriene 2 receptor on dendritic cells negatively regulates ligand-dependent allergic pulmonary inflammation","volume":"189","author":"Barrett","year":"2012","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105921_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029060","article-title":"Regulation of cysteinyl leukotriene receptor 2 expression--a potential anti-tumor mechanism","volume":"6","author":"Magnusson","year":"2011","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105921_bib20","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3345\/cep.2019.00325","article-title":"Montelukast use over the past 20 years: monitoring of its effects and safety issues","volume":"63","author":"Lee","year":"2020","journal-title":"Clin Exp Pediatr"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:35:57Z","timestamp":1768811757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2059702925017910"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105921","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Montelukast as a novel therapeutic approach in metastatic uveal melanoma harboring a CYSLTR2 mutation: a translational case report","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105921"}}